Velocity: A study of JNJ-81241459 in participants with moderate to severe plaque psoriasis
- Conditions
- Plaque PsoriasisSkin and Connective Tissue Diseases
- Registration Number
- ISRCTN76294777
- Lead Sponsor
- Janssen-Cilag International NV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped
- Sex
- All
- Target Recruitment
- 200
1. Be =18 years of age at screening, inclusive
2. Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
3. Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
4. Total Psoriasis area and severity index (PASI) >=12 at screening and baseline
5. Total Investigator global assessment (IGA) >=3 at screening and baseline
6. Candidate for phototherapy or systemic treatment for plaque Psoriasis
1. Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)
2. Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
3. Known allergies, hypersensitivity, or intolerance to JNJ-81241459 or its excipients (refer to the JNJ-81241459 IB)
4. Previously received JNJ-81241459
5. Experienced primary efficacy failure (no response within 12 weeks) or a clinical adverse event related to agents directly targeting interleukin 17 receptor (IL-17)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 12
- Secondary Outcome Measures
Name Time Method